Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0504
Abstract: Abstract Purpose: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort).… read more here.
Keywords: tls risk; tumor debulking; tls; tumor ... See more keywords
Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Ovarian Research"
DOI: 10.1186/s13048-020-00662-3
Abstract: Rationale and objectives To evaluate the impact of metabolic parameters in the peritoneal cavity on the likelihood of achieving complete tumor debulking in patients with ovarian and peritoneal cancers. Materials and methods Forty-nine patients with… read more here.
Keywords: tumor debulking; ovarian peritoneal; peritoneal cancers; peritoneal sites ... See more keywords
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.804714
Abstract: Blinatumomab is an immunotherapeutic agent with dual specificity for CD3 and CD19 that is approved for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). A steroid based pre-treatment is recommended before administering… read more here.
Keywords: tumor; refractory cell; tumor debulking; relapsed refractory ... See more keywords